Medicographia N° 114 (Vol 35 – N° 1 – 2013)

Download this issue

Editorial

• Treating type 2 diabetes: the gap between perception and evidence
  D. R. Matthews, United Kingdom

Themed articles

• Type 2 diabetes recommendations: the move toward an evidence informed consensus
  S. Colagiuri, Australia
• From randomized clinical trials to registry analysis: where is the evidence?
  M. D. Khalangot, Ukraine
• Should there be evidence-based management for all ethnic groups of diabetics or not? Management beyond borders—an Asian perspective
  S. P. Chan, Malaysia
• Should there be evidence-based management for all ethnic groups of diabetics or not? Management beyond borders—a South American perspective
  R. O. Moreira, Brazil
• Diabetes education – key principles of individual or group participation
  A. J. Sinclair, United Kingdom
• Outcome trials on the effects of glycemic control on cardiovascular risk in type 2 diabetes mellitus—What do we know and what will we learn from the ongoing trials?
  L. A. Leiter, Canada
• Glucose lowering and kidney protection: can we hit 2 birds with 1 stone?
  M. E. Cooper Australia
• The legacy effect in type 2 diabetes: fact or fiction?
  M. Marre, France
• ADVANCE-ON*: current status *Action in Diabetes and Vascular disease PreterAx and DiamicroN MR Controlled Evaluation posttrial ObservatioNal study
  S. Zoungas, J. Chalmers, Australia

Controversial Question

• HbA1c targets: does one size fit all or should they be tailored to individual patients?
  B. Bauduceau, France – F. Carrilho, Portugal – L. Czupryniak, Poland – N. Ghannam, Saudi Arabia – L. Litwak, Argentina – B. Mankovsky, Ukraine – M. Mota, D. Protasiewicz, S. G. Popa, Romania – A. Orabi, Egypt – U. Phadke, India – M. V. Shestakova, Russia – L. Smircic-
  Duvnjak, Croatia – B. Tschiedel, Brazil – Z. Visockiene, Lithuania

DIAMICRON MR

• Diamicron (gliclazide) MR: the secretagogue with clinical benefits beyond insulin secretion
  M. Ruiz, France

Interview

• How can today’s evidence-based proof in type 2 diabetes help us contain the diabetes epidemic?
  Sir M. Hirst, United Kingdom

Focus

• 
  G. Sesti, Italy

UPDATE

• The ADVANCE risk engine for cardiovascular disease prediction in the context of current strategies for cardiovascular risk evaluation in people with diabetes
  A. P. Kengne, South Africa and Australia

A Touch of France

• The keys of Egypt: Jean-François Champollion
  I. Spaak, France
  R. Adkins and L. Adkins, United Kingdom
• French doctors in Egypt with Napoleon
  C. Régnier, France